https://european-biotechnology.net/wp-content/uploads/2024/09/phoremost-team-e1726068886775.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-11 16:01:552024-09-11 16:01:55Phoremost reports Series B extension
https://european-biotechnology.net/wp-content/uploads/2024/09/SOLASTA-Bio-laboratory-002-pic-credit-Andrew-Cawley-1030x579-1.jpg
579
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-11 14:29:292024-09-11 14:29:29Funding for green insecticides
https://european-biotechnology.net/wp-content/uploads/2024/09/az-gothenburg-1030x579-1.jpeg
579
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-10 14:05:592024-09-10 14:05:59AZ’s lung cancer drug disappoints
https://european-biotechnology.net/wp-content/uploads/2024/09/Epsilogen.jpg
440
780
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-09 13:10:562024-09-09 13:10:56Epsilogen Ltd completes £12.5m Series B expansion
https://european-biotechnology.net/wp-content/uploads/2024/09/Haya-Team.png
448
614
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-04 17:17:362024-09-04 17:17:36Swiss RNA maker Haya in huge licence deal
https://european-biotechnology.net/wp-content/uploads/2024/09/Fenebrutinib-wikimedia.org_-e1725436453119.png
450
800
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-04 07:54:452024-09-04 07:54:45Roche with good interim clinical results
https://european-biotechnology.net/wp-content/uploads/2024/09/Individor-e1725432031394-1030x580-1.jpg
580
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-04 06:41:252024-09-04 06:41:25Individor set to waive AEF0117 licence after Phase IIb failure
https://european-biotechnology.net/wp-content/uploads/2024/09/Nxteras-London-site-e1725271175184.jpg
450
800
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-09-02 10:00:072024-09-02 10:00:07Nxera Pharma Ltd collects clinical US$35m milestone
https://european-biotechnology.net/wp-content/uploads/2024/08/ML.jpng_-1030x803-1.png
803
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-08-29 05:29:472024-08-29 05:29:47Researchers present AI-guided protein design tool
https://european-biotechnology.net/wp-content/uploads/2024/08/Amferia-plaster-1030x542-1.jpg
542
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2024-08-27 12:48:422024-08-27 12:48:42Amferia partners with Biokema expanding into Switzerland
Scroll to top
